<div class="container">

<table style="width: 100%;"><tr>
<td>Y3L</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>EQ-5D-Y-3L value set data</h2>

<h3>Description</h3>

<p>EQ-5D-Y-3L value set calculation data for Belgium, Brazil, China, Germany, Hungary, 
Indonesia, Japan, Netherlands, Slovenia and Spain.
</p>


<h3>Usage</h3>

<pre><code class="language-R">Y3L
</code></pre>


<h3>Format</h3>

<p>An object of class <code>data.frame</code> with 14 rows and 10 columns.
</p>


<h3>Source</h3>


<ul>
<li>
<p><strong>Belgium</strong>: Dewilde S, Roudijk B, Tollenaar NH, Ramos-Goñi JM. An EQ-5D-Y-3L Value Set for Belgium. Pharmacoeconomics. 2022 Nov 1:1–12. doi: 10.1007/s40273-022-01187-x. Epub ahead of print.  <a href="https://pubmed.ncbi.nlm.nih.gov/36316544/">PubMed</a>
</p>
</li>
<li>
<p><strong>Brazil</strong>: Espirito Santo CM, Miyamoto GC, Santos VS, Ben ÂJ, Finch AP, Roudijk B, de Jesus-Moraleida FR, Stein AT, Santos M, Yamato TP. Estimating an EQ-5D-Y-3L Value Set for Brazil. Pharmacoeconomics. 2024 Jul 2. doi: 10.1007/s40273-024-01404-9. Epub ahead of print. <a href="https://pubmed.ncbi.nlm.nih.gov/38954389/">PubMed</a>
</p>
</li>
<li>
<p><strong>China</strong>: Yang Z, Jiang J, Wang P, Jin X, Wu J, Fang Y, Feng D, Xi X, Li S, Jing M, Zheng B, Huang W, Luo N. Estimating an EQ-5D-Y-3L Value Set for China. Pharmacoeconomics. 2022 Nov 18. doi: 10.1007/s40273-022-01216-9. Epub ahead of print. <a href="https://pubmed.ncbi.nlm.nih.gov/36396878/">PubMed</a>
</p>
</li>
<li>
<p><strong>Germany</strong>: Kreimeier S, Mott D, Ludwig K, Greiner W; IMPACT HTA HRQoL Group. EQ-5D-Y Value Set for Germany. Pharmacoeconomics. 2022 May 23:1–13. doi: 10.1007/s40273-022-01143-9. Epub ahead of print. <a href="https://pubmed.ncbi.nlm.nih.gov/35604633/">PubMed</a>
</p>
</li>
<li>
<p><strong>Hungary</strong>: Rencz F, Ruzsa G, Bató A, Yang Z, Finch AP, Brodszky V. Value Set for the EQ-5D-Y-3L in Hungary. Pharmacoeconomics. 2022 Sep 20:1–11. doi: 10.1007/s40273-022-01190-2. Epub ahead of print. <a href="https://pubmed.ncbi.nlm.nih.gov/36123448/">PubMed</a>
</p>
</li>
<li>
<p><strong>Indonesia</strong>: Fitriana TS, Roudijk B, Purba FD, Busschbach JJV, Stolk E. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values. Pharmacoeconomics. 2022 Nov 9. doi: 10.1007/s40273-022-01210-1. Epub ahead of print.  <a href="https://pubmed.ncbi.nlm.nih.gov/36348155/">PubMed</a> 
</p>
</li>
<li>
<p><strong>Japan</strong>: Shiroiwa T, Ikeda S, Noto S, Fukuda T, Stolk E. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan. Med Decis Making. 2021 Mar 23:272989X211001859. doi: 10.1177/0272989X211001859. Epub ahead of print. <a href="https://pubmed.ncbi.nlm.nih.gov/33754886/">PubMed</a>
</p>
</li>
<li>
<p><strong>Netherlands</strong>:Roudijk B, Sajjad A, Essers B, Lipman S, Stalmeier P, Finch AP. A Value Set for the EQ-5D-Y-3L in the Netherlands. Pharmacoeconomics. 2022 Oct 10:1–11. doi: 10.1007/s40273-022-01192-0. Epub ahead of print. <a href="https://pubmed.ncbi.nlm.nih.gov/36216977/">PubMed</a>
</p>
</li>
<li>
<p><strong>Slovenia</strong>: Prevolnik Rupel V, Ogorevc M; IMPACT HTA HRQoL Group. EQ-5D-Y Value Set for Slovenia. Pharmacoeconomics. 2021 Feb 10. doi: 10.1007/s40273-020-00994-4. Epub ahead of print. <a href="https://pubmed.ncbi.nlm.nih.gov/33565048/">PubMed</a>
</p>
</li>
<li>
<p><strong>Spain</strong>: Ramos-Goñi JM, Oppe M, Estévez-Carrillo A, Rivero-Arias O; IMPACT HTA HRQoL Group. Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data. Value in Health. 2021 Dec 04. doi: 10.1016/j.jval.2021.10.013.
</p>
</li>
</ul>
</div>